Issue 22 - June 2013
subscriber list is managed using Mailman, the GNU Mailing List
Manager. To subscribe or unsubscribe, please visit https://mail.cs.ualberta.ca/mailman/listinfo/MetaboNews
Current and back issues of this newsletter can be viewed from the newsletter archive (http://www.metabonews.ca/archive.html).
1) Partnership Spotlight
|| Lecturer in
Metabolomics, School of Biosciences, University of
Birmingham (UK) and Director of the International
Dr Warwick (Rick) Dunn was awarded a BSc (Hons) in Chemistry with Analytical Chemistry and Toxicology and a Doctor of Philosophy from The University of Hull in the UK. Subsequently, Warwick has gained over 15 years of expertise in analytical chemistry and mass spectrometry, both in industry and academia. Initially he tackled (bio)-analytical problems ranging from the placement of mass spectrometers on to industrial chemical process plants for his PhD studies to the characterisation and quality assurance of fish and vegetable oils at Croda Chemicals. In 2003 Warwick returned to academia, moving to the University of Manchester where he developed and applied mass spectrometry platforms in metabolomics and systems biology investigations. He initially studied Saccharomyces cerevisiae and for the last seven years Warwick’s major focus has been on the application of metabolomics in biomedical and clinical applications. Warwick moved to the University of Birmingham in early 2013 to expand his research in applying metabolomics and integrated systems medicine approaches in biomedical and clinical research and in developing new tools for metabolite annotation and identification.
3) Biomarker Beacon
|3 Jun 2013
The Metabolomics Innovation Centre (TMIC)—One of five Genome Canada-funded Science and Technology Innovation Centres
As part of its commitment to leading-edge research, Genome Canada supports a number of Science and Technology Innovation Centres across the country. These S&T Innovation Centres provide researchers with access to cutting-edge technologies such as DNA sequencing, RNA expression analysis, protein identification, metabolite analysis, bioinformatics and large-scale data analysis, as well as access to new methods and protocols.
As of May 2013, $29 million will be invested over two years to sustain the S&T Innovation Centres until 2014-15. Read more on the five S&T Innovation Centres located across Canada:
Genomics Innovation Centre at the B.C. Cancer Agency Genome Sciences Centre
This leading international Centre for genomics and bioinformatics research supports scientists in BC and around the world in addressing critical questions in the life sciences, with a focus on human cancers. As one of the largest capacity genomics centres of its type in Canada, the Centre specializes in high-throughput, large-scale genome research activities including cancer genetics, bioinformatics, DNA sequencing (the process of determining the precise order of nucleotides within a DNA molecule), data analysis, gene expression profiling, and technology development. The Centre also provides training in bioinformatics for health researchers.
McGill University and Genome Quebec Innovation Centre
A world-class research facility for genomics, this Centre has renowned expertise in complex genetic disorders such as cardiac disease, asthma and Type 2 diabetes. It provides a comprehensive suite of services, including complete DNA and RNA analysis, large-scale genomics, as well as genotyping and bioinformatics.
The Centre for Applied Genomics
Affiliated with the world-renowned SickKids Hospital in Toronto, The Centre for Applied Genomics conducts groundbreaking research in genomics including service and training support for academic, government, and private sector scientists worldwide. It provides a wide variety of services including biobanking (a facility that stores biological samples (usually human) for use in research)., informatics, microarray analysis (analyzing many genes in a single experiment quickly and efficiently) and DNA sequencing.
The Metabolomics Innovation Centre
When we talk about our “metabolism”, we’re really talking about all of the chemical processes that take place in our cells that keep us alive. Metabolites are the substances produced by those processes or that are required for those processes to occur. Metabolomics is the study of these metabolites.
This unique Centre, located in Edmonton, Alberta, and Victoria, British Columbia offers a wide range of cutting-edge metabolomic services for clinical trials research, biomedical studies, bioproducts studies, nutrient profiling and environmental testing. The Centre is capable of identifying and quantifying up to 2,000 different chemicals from certain biological samples—about five times more than any other service currently available.
University of Victoria-Genome BC Proteomics Centre
Proteomics is the study of the structure, function and interactions of proteins. This is critical because proteins represent the actual functional molecules in a cell. For example, when mutations occur in DNA, it is the proteins that are ultimately affected.
This Centre provides world-class services and support in identifying and characterizing proteins. It also specializes in quantitative proteomics (identifying differences between samples), enabling researchers to pinpoint differences between healthy and diseased patients. Research at the Centre is focused on developing new technologies in structural proteomics, clinical proteomics, and protein imaging with the ultimate goal of applying these technologies to customer research projects.
For more information on the S&T Innovation Centres, view the following link on Genome Canada’s website.
Source: Genome Alberta Genomics Blog
|3 Jun 2013
Harper Government and Genome Canada launch new program to accelerate genomics discovery to market
The Honourable Gary Goodyear, Minister of State (Science and Technology), announced the launch of a new Genome Canada program designed to move genomics-based solutions from laboratories to the marketplace. The Genomic Applications Partnership Program (GAPP) is also intended to stimulate investment from private and public partners to fund projects that address real world challenges and opportunities in the field of genomics.
“Our Government recognizes that genomics science is at the core of the economic activity of life sciences research,” said Minister Goodyear. “More than ever before, the field of genomics is equipping Canadian businesses with cutting-edge science and technologies that are not only helping to address the challenges we face but are also driving economic growth and creating high quality jobs.”
The GAPP is Genome Canada's newest flagship partnership program that will increase collaboration between genomics scientists and "users" of genomics research (industry, government, non-profit or other organizations). The Harper Government, through Genome Canada, is committing $30 million to the program, and through regional Genome Centres, will leverage additional funding from partners and industry, rendering this a $90 million investment in made-in-Canada genomics research and development.
"The program was designed based on extensive consultation both with the genomics research community and the community of users of genomics research to ensure it was meeting clearly defined needs,” said Dr. Pierre Meulien, President and CEO of Genome Canada. “We expect the GAPP to result in early-stage products, tools and processes that will bring genomics research to application and market, thereby stimulating Canadian innovation."
To further bolster Canada's genomics research enterprise, Minister Goodyear also announced $29 million in renewed funding for five world-class genomics research facilities located across Canada. This funding renewal comes after a rigorous review of the Centres’ operations by an International Review Committee. The Science and Technology Innovation Centres provide access to genomic, proteomic, metabolomic and bioinformatics technologies not only for Genome Canada-funded projects, but also for the broader research community. In addition, the Centres assist scientists by advising on research study design and the appropriate technologies required to carry out their research proposals.
To help achieve important future genomics research breakthroughs, Economic Action Plan 2012 provided $60 million for Genome Canada to launch its new GAPP program, and to sustain the Science and Technology Centres until 2014–15. Of this total, $26 million is attributed to the GAPP, $29 million is provided to renew the operations of Genome Canada’s five Science and Technology Innovation Centres and $5 million to support Canadian leadership on two international consortia, the Structural Genomics Consortium and International Barcode of Life Consortium. An additional $4 million from Genome Canada’s ongoing budget will be allocated to the GAPP.
Since 2006, the Harper Government has provided more than $9 billion in new funding for initiatives to support science, technology and the growth of innovative firms. These investments have helped to foster a world-class research and innovation system. Economic Action Plan 2013 proposes to build on this strong foundation, helping to position Canada for sustainable, long-term prosperity and a higher quality of life for Canadians. Among other things, Economic Action Plan 2013 provides $165 million to further support Genome Canada’s multi-year strategic plan.
Further details related to this announcement are available on Genome Canada’s website at www.genomecanada.ca.
Genomics Definition: http://www.metabonews.ca/Jun2013/news/GAPP/Genomics Definition.pdf
GAPP Brochure: http://www.metabonews.ca/Jun2013/news/GAPP/GAPP Brochure.pdf
Source: Genome Canada
|15 May 2013
Alberta Innovates - Health Solutions awards $375,000 to develop new colon cancer screening test by Metabolomic Technologies Inc.
Metabolomic Technologies Inc. (MTI), an Alberta-based company that develops advanced metabolomic-based diagnostic tests for chronic diseases, was recently named the recipient of a Knowledge Translation Strategic Initiative Grant by Alberta Innovates - Health Solutions (AIHS) in the amount of $375,000 through the Alberta Cancer Prevention Legacy Fund (ACPLF).
"AIHS has an ambitious mandate to support Alberta's health research and innovation priorities, and MTI has demonstrated the kind of high quality activity that makes it an ideal recipient for this award," says Dr. Pamela Valentine, Chief Operating Officer of AIHS. "Supporting leading home-grown healthcare innovators like MTI is the key to our mandate of improving the quality of life for Albertans."
Following on completion of MTI's 1,200 patient clinical trial, this new funding will support validation trials for MTI's patented colonic polyp (polyps can be precursors to colon cancer) screening diagnostics test: PolypDx™.
The AIHS funding will enable MTI to continue to work with Alberta Health Services (AHS) to validate PolypDx™ in Lethbridge, Alberta. This is an opportunity for an Alberta-based test to be developed in the province and directly impact the health of Albertans. Currently, there are approximately 300,000 Albertans who need to be screened for colon cancer.
MTI's PolypDx™ represents exciting next generation technology currently in development.
This grant allows MTI to work directly with DynaLIFEDx to optimize this test for large scale population screening. DynaLIFEDx, an Alberta-based medical laboratory with global reach, has the capability to help MTI accommodate large scale population screening of PolypDx™ in Alberta, nationally and internationally.
"DynaLIFEDx is very pleased to be working with MTI to develop mainstream clinical application for this technology. DynaLIFEDx is a proud partner of the University of Alberta and AHS to actively drive the application of new technology into mainstream healthcare delivery. MTI is a great example of what is possible right here in Alberta. MTI is a success story of technology developed in Alberta that will see Albertan's benefit first," says Jason Pincock, Chief Executive Officer of DynaLIFEDx.
In addition to being a more attractive alternative to traditional cancer screening tests, MTI's PolypDx™ demonstrates higher detection accuracy than current fecal-based tests. The superior accuracy of MTI's diagnostic tests will be a game-changer in the early detection and prevention of colon cancer, which was responsible for 720 deaths in Alberta last year (Colorectal Cancer Association of Canada, 2012).
"Typically, companies like MTI would need to explore international partnerships to validate tests like PolypDx™. The successful launch of these partnerships allows MTI the opportunity to collaborate with Alberta partners in the early diagnosis of polyps and colon cancer," states MTI Chief Executive Officer Reg Joseph.
PolypDx™ was developed at the University of Alberta by AIHS funded researcher Dr. Richard Fedorak, Dr. Haili Wang and their team at MTI, a U of A spin-off company incorporated with the help of business incubator TEC Edmonton.
Thanks to the Knowledge Translation Strategic Initiative Grant from AIHS, MTI now has the means to conduct validation trials of PolypDx™ within "real-life" clinical environments.
For more information about MTI, visit www.metabolomictechnologies.ca.
Source: Canada Newswire
|3 May 2013
Chances are you’ve never heard the word metabolomics (pronounced metabo-LOH-mics) but it just might revolutionize medical diagnostics around the world — and the U of A stands at the global epicentre of this emerging field.
“It’s clinical chemistry on steroids,” explains David Wishart, project leader for the U of A’s Human Metabolome Project. Metabolomics seeks to identify and catalogue every chemical we produce in our bodies, and to look for the patterns that correspond to various illnesses and conditions. Instead of looking for one or two compounds — for example, blood glucose — metabolomics measures hundreds or even thousands of compounds all at once.
By doing so, metabolomics vastly expands the amount of information that we can derive from a single tissue or fluid sample, says Wishart. “In the past, it was like looking at the world through a keyhole. But now, we can look at the world through a picture window.”
In other words, metabolomics allows diagnosticians to see the big picture. “Blood glucose tells you if you have diabetes or not,” explains Wishart. “But there’s a whole bunch of other compounds that can tell you how bad the diabetes is, whether it’s going to progress, or even if you’re going to get diabetes.”
That kind of detail opens the door to personalized health care. “You can actually have a metabolic profile that could be used to diagnose, or predict, or prognosticate, or assess the risk for a whole bunch of different conditions.”
Eventually, Wishart hopes, a urine sample could be as useful a diagnostic tool as a Star Trek tricorder (if not quite as sexy).
The Human Metabolome Project, launched by Wishart’s lab in 2005, has catalogued about 40,000 different chemicals found in the human body. Although the project hasn’t yet made its way into everyday medical practice, that day is definitely coming. Several companies, including three in Edmonton, have already started developing specific tests based on the data, including one for pre-colon cancer and another for HIV.
Meanwhile, the U of A’s Human Metabolome Project database is accessed by millions around the globe every year. It just might be time for a new sign on Gateway Boulevard: “Welcome to Edmonton — City of Metabolomics.”
6) Metabolomics Events
|1-7 June 2013||
GRC on Computational NMR
and Associated Seminar on Metabolomic NMR
The meeting is the eighth GRC on Computational NMR and the first to include a dedicated Seminar for graduate students and postdocs. The focus of the GRS is to discuss new contributions in computational Nuclear Magnetic Resonance to the growing field of metabolomics and will feature a keynote talk by David Wishart, University of Alberta, and discussions led by experts in metabolomic NMR as a complement to oral presentations by graduate students and postdocs.
For more information: http://www.grc.org/programs.aspx?year=2013&program=grs_bionmr
For registration: http://www.grc.org/application.aspx?id=15572
We do hope that you will both consider attending and provide this information to your students and postdocs and encourage them join us in Vermont for what we anticipate will be an enjoyable and stimulating meeting.
|1-4 Jul 2013||
9th Annual International
Meeting of the Metabolomics Society
We expect this to be the 'must attend' meeting in 2013 for researchers from around the world, where the best speakers in the world and rising stars of the future will present their work in a mixture of plenary and parallel sessions. The Metabolomics Society came into being with the development of the Metabolomics as a discipline and as a result provides a focus for the most varied aspects of the subject ranging from microbes to man. As a result of this it brings together a diverse mixture of scientists from many disciplines, which produces very stimulating meetings.
One of the main aims of the conference will be to create a unique platform for young scientists. Come and listen and talk to the top experts in the field. Find out about the latest exciting technologies that can advance your own research, but most of all come and enjoy Scotland's largest and most vibrant city and the beautiful countryside around it.
We look forward to welcoming you to Glasgow in 2013!
Chair, Local Organising Committee
Metabolomics Glasgow 2013
For more information, visit http://www.metabolomics2013.org/.
|4-5 Jul 2013||
1st International Workshop
on The food metabolome and biomarkers for
Diet is well recognized as a major determinant of health and some dietary factors are known to modify risk for various non-communicable diseases. However results of epidemiological studies are often contradictory or inconsistent and it is still difficult to draw precise dietary recommendations at the population or individual level to best prevent chronic diseases. These difficulties are notably explained by a lack of accuracy and precision in dietary assessment, due to limitations commonly met with tools such as food frequency questionnaires classically used in epidemiological studies. In addition, improved tools are also needed to monitor dietary exposures in nutritional intervention studies on the effects of the diet on health and diseases.
Biomarkers provide a more objective measure of dietary exposure:
The purpose of the present workshop is to convene for the first time key experts in metabolomics, nutrition and epidemiology in order to define the most promising and shortest routes to mine the food metabolome and identify biomarkers needed to better understand the role of the diet in disease aetiology.
General objectives of the workshop
|2-4 Jul 2013||
3rd European Lipidomic
For more information, visit http://mab.uochb.cas.cz/iochb/ELM2013/.
|8-9 Jul 2013||
Informatics and Statistics
for Metabolomics (2013)
Target Audience: This course is intended for graduate students, post-doctoral fellows, clinical fellows and investigators who are interested in learning about both bioinformatic and cheminformatic tools to analyze and interpret metabolomics data.
Prerequisite: Your own laptop computer. Minimum requirements: 1024x768 screen resolution, 1.5GHz CPU, 1GB RAM, recent versions of Windows, Mac OS X or Linux (Most computers purchased in the past 3-4 years likely meet these requirements). If you do not access to a laptop, you may loan one from the CBW. Please contact email@example.com for more information.
Pre-Readings: You are expected to have completed the following tutorials in R beforehand. The tutorial should be very accessible even if you have never used R before. Please complete the following: R Tutorial
Advertising poster for this workshop: https://bioinformatics.ca/files/InformaticsMetabolomics_2013.pdf
For more information, visit http://bioinformatics.ca/workshops/2013/informatics-and-statistics-metabolomics-2013.
|6 Aug 2013||
Frontiers in Nutritional
Science: The Inaugural Australian Symposium on
About the event
Nutritional Metabolomics is an exciting, emerging frontier field of science.
Metabolomics (measuring metabolites from physiological process) provide information, 'windows into the body', which have the potential to transform how we measure health, how we identify and monitor people most at risk of disease, and the way we monitor food intake.
The event will provide food and health science professionals and researchers, an exciting insight into how this new science can be applied to better understand the ways in which food, diet and the body interact.
To stimulate interest and collaboration in this frontier field of health sciences, we are organising a symposium which aims to explore opportunities for using metabolomics to improve human health by nutritional means.
This one day symposium will bring together international and national experts to provide a comprehensive, up-to-date overview of this fast growing field.
The event will provide food and health science professionals and researchers, an exciting insight into how this new science can be applied to better understand the ways in which food, diet and the body interact.
Topics to be covered include:
|13-17 Aug 2013||
Metabolic Signaling &
Disease: From Cell to Organism
Daniel Kelly, Sanford-Burnham Medical Research Institute
Mitchell Lazar, University of Pennsylvania
Susanne Mandrup, University of Southern Denmark
We are pleased to announce the first Cold Spring Harbor meeting on Metabolic Signaling & Disease: From Cell to Organism which will begin on Tuesday evening, August 13 and end at noon on Saturday, August 17, 2013.
Metabolic regulation is at the intersection of many scientific fields, ranging from basic biochemistry and molecular biology to physiology, to the study of disease pathogenesis. Currently, a major challenge for these diverse fields is to define commonalities and differences in metabolic pathways and their regulation, and determine the role of these processes for physiology and disease states. This meeting will fill an important gap by bringing together outstanding researchers focused on diverse pathways, cell types, or diseases with a common theme of understanding how metabolism is regulated in physiology and disease states.
For more information, visit http://meetings.cshl.edu/meetings/2013/metab13.shtml.
|9-11 Sep 2013||
Environmental ‘Omics Synthesis Conference
The aim of this conference is to bring together researchers and organisations from a range of disciplines representing those involved in the development of new approaches in data handling and generation with those harnessing ‘Omics to advance key areas in Environmental Science. It is our hope is that the resulting interaction and exchange of ideas will lead to novel approaches, new collaborations and the establishment of a wider integrated ‘Omics community.
iEOS2013 – Announcement Poster: http://environmentalomics.org.gridhosted.co.uk/wp-content/uploads/2013/03/iEOS2013-Final-Announcement.pdf
For more information, visit http://environmentalomics.org/iEOS2013/.
|1-3 Oct 2013||
The 10th International
Symposium on Milk Genomics and Human Health
The venue for this year's event is the U.C. Davis Conference Center located on the University of California, Davis campus in the United States.
The three day event will bring together international experts in nutrition, genomics, bioinformatics and milk research to discuss and share the latest breakthroughs and their implications.
The Annual Symposium is our flagship event that features scientific research related to milk and human health done throughout the world. The symposium draws from the diversity of its memberships to cover the breath of genomics themes that reflect the interest of the Consortium. The goal of the Consortium is to bring together the research and dairy communities to share, translate, and interpret data that are happening within the fields of the "-omics" science.
For more information, visit http://milkgenomics.org/symposia/the-10th-international-symposium-on-milk-genomics-and-human-health-october-1-3-2013.
|7-11 Oct 2013||
SLC-Tjärnö marinebiological laboratory
Application should include a short motivation (<1 page) and a brief CV. Submit by E-mail to firstname.lastname@example.org
Application deadline 15th of August 2013
Prof. Georg Pohnert, Biorganic Analytics, Friedrich Schiller University, Jena
Prof. Johan Trygg, Department of Chemistry, Umeå University
Dr. Ulf Sommer, NERC Metabolomics Facility, University of Birmingham
Contact and inquiries:
Erik Selander email@example.com
Göran Nylund firstname.lastname@example.org
Course Flyer: http://www.metabonews.ca/May2013/events/Metabolomics%20course%20flyer.pdf
11th Annual Metabolomics
7) Metabolomics Jobs
|Assistant/Associate Professor Tenure Track Positions||McGill University||Montreal, Canada||30-May-2013||31-Aug-2013
|Development, implementation and use of NMR and atmospheric pressure ionization mass spectrometry databases for metabolomics||MetaboHUB||
Bordeaux Metabolome Facility, INRA
Bordeaux Center, F-33140 Villenave
|Proteomics and Metabolomics Postdoc (m/f)||Leiden University Medical Center||Leiden, Netherlands||4-Jun-2013||1-Jul-2013
|Metabolomics platform technical manager||Gustave Roussy Cancer Institute||Villejuif, France||8-May-2013||1-Jul-2013
|Postdoctoral Scientist Bioinformatics - Metabolomics||Singapore Institute for Clinical Sciences (A*STAR)||Singapore, Singapore||21-May-2013||21-Jun-2013
|LC-MS Metabolomics Specialist||Metabolomic Discoveries||Potsdam, Germany||26-Apr-2013||21-Jun-2013||Metabolomics Society|
|Postdoc position||Laboratory for Inherited Metabolic Disorders and Metabolomics Medical Group, Faculty of Medicine and Dentistry, Palacky University||Olomouc, Czech Republic||4-Jun-2013||15-Jun-2013
|Research Associate Position in Metabolomics||Georgetown University||Washington D.C., USA||6-May-2013||Metabolomics Society|
|Postdoctoral position in malaria mass spectrometry-based metabolomics||Pennsylvania State University||
College, Pennsylvania, USA
|Full-Time Research Coordinator||University of Alberta||
Ian J. Forsythe, M.Sc.MetaboNews
University of Alberta
221 Athabasca Hall
Edmonton, AB, T6G 2E8, Canada
This newsletter is produced by The Metabolomics Innovation Centre (TMIC, http://www.metabolomicscentre.ca/) for the benefit of the worldwide metabolomics community.
A single source destination for fee-for-service metabolic profiling including comprehensive metabolite identification, quantification, and analysis